Genomic profiles of BRAF inhibitor resistance mechanisms in metastatic colorectal cancer.

e15527Background: BRAF mutations are present in 5-10% of metastatic colorectal cancers (mCRCs). Patients with mCRC whose tumors harbor BRAF V600 mutation generally respond poorly to standard chemot...